Morgan Stanley Matinas Bio Pharma Holdings, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	SELL	$0.15 - $0.37 $226 - $557	-1,507 Reduced 3.17%	46,000 $7,000
Q2 2024 Aug 14, 2024	SELL	$0.15 - $0.37 $226 - $557	-1,507 Reduced 3.17%	46,000 $7,000
Q1 2024 Oct 17, 2024	BUY	$0.19 - $0.3 $286 - $452	1,507 Added 3.28%	47,507 $12,000
Q1 2024 Aug 16, 2024	BUY	$0.19 - $0.3 $3,801 - $6,002	20,007 Added 72.75%	47,507 $12,000
Q1 2024 May 15, 2024	BUY	$0.19 - $0.3 $3,801 - $6,001	20,006 Added 72.75%	47,507 $12,000
Q4 2023 Aug 16, 2024	SELL	$0.12 - $0.64 $2,220 - $11,840	-18,500 Reduced 40.22%	27,500 $6,000
Q4 2023 Feb 13, 2024	SELL	$0.12 - $0.64 $300 - $1,600	-2,500 Reduced 8.33%	27,501 $6,000
Q2 2023 Aug 14, 2023	SELL	$0.35 - $0.72 $2,533 - $5,211	-7,238 Reduced 19.44%	30,001 $10,000
Q1 2023 May 15, 2023	SELL	$0.39 - $0.6 $674 - $1,037	-1,729 Reduced 4.44%	37,239 $17,000
Q4 2022 Feb 14, 2023	BUY	$0.46 - $42.69 $8,777 - $814,567	19,081 Added 95.95%	38,968 $19,000
Q3 2022 Nov 14, 2022	SELL	$0.63 - $33.0 $12,588 - $659,406	-19,982 Reduced 50.12%	19,887 $13,000
Q2 2022 Oct 27, 2022	SELL	$0.63 - $0.96 $8,251 - $12,574	-13,098 Reduced 24.73%	39,869 $31,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $0.96 $8,251 - $12,574	-13,098 Reduced 24.73%	39,869 $31,000
Q1 2022 Oct 27, 2022	BUY	$0.5 - $1.06 $6,549 - $13,883	13,098 Added 32.85%	52,967 $43,000
Q1 2022 May 13, 2022	SELL	$0.5 - $1.06 $9,254 - $19,618	-18,508 Reduced 25.89%	52,967 $43,000
Q4 2021 Feb 14, 2022	BUY	$0.92 - $1.22 $15,654 - $20,759	17,016 Added 31.25%	71,475 $72,000
Q3 2021 Nov 15, 2021	BUY	$0.67 - $1.51 $36,487 - $82,233	54,459 New	54,459 $71,000

Others Institutions Holding MTNB

# of Institutions

Shares Held

3.52M

Call Options Held

Put Options Held

View Full List

About Matinas BioPharma Holdings, Inc.

Ticker MTNB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,864,992
Market Cap $124M
Description
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic ...

More about MTNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account